DOI QR코드

DOI QR Code

Treatment of Drug-Induced Erythema Multiforme: Case Report

  • Lee, Hae-Ohk (Department of Oral Medicine, Dental Research Institute, Dental and Life Science Institute, School of Dentistry, Pusan National University) ;
  • Ju, Hye-Min (Department of Oral Medicine, Dental Research Institute, Dental and Life Science Institute, School of Dentistry, Pusan National University) ;
  • Lee, Ji-Yeon (Department of Oral Medicine, Dental Research Institute, Dental and Life Science Institute, School of Dentistry, Pusan National University) ;
  • Jeon, Hye-Mi (Dental Clinic Center, Pusan National University Hospital) ;
  • Kim, Kyung-Hee (Department of Oral Medicine, Inje University Busan Paik Hospital) ;
  • Ok, Soo-Min (Department of Oral Medicine, Dental Research Institute, Dental and Life Science Institute, School of Dentistry, Pusan National University) ;
  • Ahn, Yong-Woo (Department of Oral Medicine, Dental Research Institute, Dental and Life Science Institute, School of Dentistry, Pusan National University) ;
  • Jeong, Sung-Hee (Department of Oral Medicine, Dental Research Institute, Dental and Life Science Institute, School of Dentistry, Pusan National University)
  • Received : 2019.11.18
  • Accepted : 2019.12.11
  • Published : 2019.12.30

Abstract

Erythema multiforme (EM) is an inflammatory immune-mediated mucosal disease. EM is classified as EM minor or EM major, depending on the severity of symptoms. Most patients with minor or major forms of EM have oral lesions. EM can occur as a result of adverse drug reactions but this is difficult to establish. Several indicators have been developed that can be used as a criterion of evaluation to ensure objectivity in identifying the causality of adverse drug reactions. The Naranjo algorithm was used in the evaluation to ensure objectivity in identifying the causality of adverse drug reactions. There were two cases of patients suspected of having EM induced by drugs. They were both assessed using the Naranjo algorithm to confirm the causality of the disease.

References

  1. Huff JC, Weston WL, Tonnesen MG. Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol 1983;8:763-775. https://doi.org/10.1016/S0190-9622(83)80003-6
  2. Scully C, Bagan J. Oral mucosal diseases: erythema multiforme. Br J Oral Maxillofac Surg 2008;46:90-95. https://doi.org/10.1016/j.bjoms.2007.07.202
  3. Bean SF, Quezada RK. Recurrent oral erythema multiforme. Clinical experience with 11 patients. JAMA 1983;249:2810-2812. https://doi.org/10.1001/jama.1983.03330440048031
  4. Lozada-Nur F, Gorsky M, Silverman S Jr. Oral erythema multiforme: clinical observations and treatment of 95 patients. Oral Surg Oral Med Oral Pathol 1989;67:36-40. https://doi.org/10.1016/0030-4220(89)90299-5
  5. Cote B, Wechsler J, Bastuji-Garin S, Assier H, Revuz J, Roujeau JC. Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 1995;131:1268-1272. https://doi.org/10.1001/archderm.1995.01690230046008
  6. Farthing P, Bagan JV, Scully C. Mucosal disease series. Number IV. Erythema multiforme. Oral Dis 2005;11:261-267. https://doi.org/10.1111/j.1601-0825.2005.01141.x
  7. French LE, Prins C. Erythema multiforme, Stevens-Johnson Syndrome and toxic epidermal necrolysis. In: Bolognia JL, Jorizzo JL, Rapini RP, et al, eds. Dermatology. 2nd ed. London: Mosby Elsevier; 2008. pp. 287-300.
  8. Samim F, Auluck A, Zed C, Williams PM. Erythema multiforme: a review of epidemiology, pathogenesis, clinical features, and treatment. Dent Clin North Am 2013;57:583-596. https://doi.org/10.1016/j.cden.2013.07.001
  9. Aurelian L, Ono F, Burnett J. Herpes simplex virus (HSV)-associated erythema multiforme (HAEM): a viral disease with an autoimmune component. Dermatol Online J 2003;9:1.
  10. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000;356:1587-1591. https://doi.org/10.1016/S0140-6736(00)03137-8
  11. Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996;134:710-714. https://doi.org/10.1111/j.1365-2133.1996.tb06976.x
  12. Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 1997;17:374-389. https://doi.org/10.2165/00002018-199717060-00004
  13. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-1259. https://doi.org/10.1016/S0140-6736(00)02799-9
  14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245. https://doi.org/10.1038/clpt.1981.154
  15. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA 1979;242:623-632. https://doi.org/10.1001/jama.1979.03300070019017
  16. Son MK, Lee YW, Jung HY, et al. Comparison of the naranjo and WHO-uppsala monitoring centre criteria for causality assessment of adverse drug reactions. Korean J Med. 2008;74:181-7.
  17. Fischer TW, Bauer HI, Graefe T, Barta U, Elsner P. Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide. Dermatology 2003;207:386-389. https://doi.org/10.1159/000074120
  18. Omoregie FO, Ukpebor M, Saheeb BD. Methotrexate-induced erythema multiforme: a case report and review of the literature. West Afr J Med 2011;30:377-379.